Diffusive vs. convective therapy: Effects on mediators of inflammation in patients with severe systemic inflammatory response syndrome

被引:162
作者
Kellum, JA [1 ]
Johnson, JP
Kramer, D
Palevsky, P
Brady, JJ
Pinsky, MR
机构
[1] Univ Pittsburgh, Med Ctr, Dept Anesthesiol Crit Care Med, Pittsburgh, PA 15261 USA
[2] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA USA
关键词
continuous venovenous hemofiltration; continuous venovenous hemodialysis; tumor necrosis factor-alpha; hemofiltration; hemodialysis; cytokines; systemic immune response syndrome; sepsis; blood purification; acute renal failure;
D O I
10.1097/00003246-199812000-00027
中图分类号
R4 [临床医学];
学科分类号
1002 ; 100602 ;
摘要
Objective: to compare two forms of continuous renal replacement therapy, continuous venovenous hemofiltration (CVVH) vs. continuous venovenous hemodialysis (CVVHD), in terms of the removal of inflammatory mediators from the blood of patients with systemic inflammatory response syndrome and acute renal failure. Design: Randomized crossover, clinical study. Setting: University teaching hospital. Patients: Thirteen patients with systemic inflammatory response syndrome and acute renal failure receiving continuous renal replacement therapy. Intervention: Patients were randomized to receive either convective clearance using CVVH or diffusive clearance using CVVHD for the first 24 hrs, followed by the other modality for 24 hrs. All treatments utilized AN69 hemofilters. CVVH was performed with an ultrafiltration rate of 2 L/hr and CVVHD with a dialysis outflow rate of 2 L/hr. Measurements and Main Results: Plasma and ultrafiltrate concentrations of tumor necrosis factor (TNF)-alpha, interleukin (IL)-6, IL-10, and sL-selectin were measured at 0, 1, 3, 6, 12, and 24 hrs by radioimmunoassay. Plasma endotoxin concentrations were also measured at 0, 12, and 24 hrs by chromogenic assay. CVVH was associated with a 13% decrease in plasma TNF-alpha concentrations compared with a 23% increase while on CVVHD (p < .05). Mean plasma concentrations of IL-6, IL-10, and sL-selectin were unchanged over time and between therapies. Only minimal amounts of mediators were recovered in the effluents with either therapy except for IL 6. The clearances for IL-6 were different between therapies, 1.9 +/- 0.8 (SD) mL/min for CVVHD and 3.3 +/- 1.5 mL/min for CVVH, (p < .01). Plasma endotoxin concentrations were not different between therapies. Conclusion: CVVH resulted in a decrease in plasma TNF a concentrations as compared with CVVHD, while the type of transport mechanism used did not influence plasma concentrations of IL-6, IL-10, soluble L-selectin, or endotoxin. Differences in clearance for IL-6 between CVVH and CVVHD did not translate into significant changes in circulating IL-6 concentrations.
引用
收藏
页码:1995 / 2000
页数:6
相关论文
共 32 条
[1]   THE HYPERMETABOLISM - MULTIPLE ORGAN FAILURE SYNDROME [J].
BARTON, R ;
CERRA, FB .
CHEST, 1989, 96 (05) :1153-1160
[3]   CONTINUOUS VENOVENOUS HEMOFILTRATION WITH DIALYSIS REMOVES CYTOKINES FROM THE CIRCULATION OF SEPTIC PATIENTS [J].
BELLOMO, R ;
TIPPING, P ;
BOYCE, N .
CRITICAL CARE MEDICINE, 1993, 21 (04) :522-526
[4]   INTERLEUKIN-6 AND INTERLEUKIN-8 EXTRACTION DURING CONTINUOUS VENOVENOUS HEMODIAFILTRATION IN SEPTIC ACUTE-RENAL-FAILURE [J].
BELLOMO, R ;
TIPPING, P ;
BOYCE, N .
RENAL FAILURE, 1995, 17 (04) :457-466
[5]   TOWARD AN EPIDEMIOLOGY AND NATURAL-HISTORY OF SIRS (SYSTEMIC INFLAMMATORY RESPONSE SYNDROME) [J].
BONE, RC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1992, 268 (24) :3452-3455
[6]   PLATELET-ACTIVATING-FACTOR RECEPTOR ANTAGONIST BN-52021 IN THE TREATMENT OF SEVERE SEPSIS - A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER CLINICAL-TRIAL [J].
DHAINAUT, JFA ;
TENAILLON, A ;
LETULZO, Y ;
SCHLEMMER, B ;
SOLET, JP ;
WOLFF, M ;
HOLZAPFEL, L ;
ZENI, F ;
DREYFUSS, D ;
MIRA, JP ;
DEVATHAIRE, F ;
GUINOT, P .
CRITICAL CARE MEDICINE, 1994, 22 (11) :1720-1728
[7]   RECOMBINANT HUMAN INTERLEUKIN-1 RECEPTOR ANTAGONIST IN THE TREATMENT OF PATIENTS WITH SEPSIS SYNDROME - RESULTS FROM A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL [J].
FISHER, CJ ;
DHAINAUT, JFA ;
OPAL, SM ;
PRIBBLE, JP ;
BALK, RA ;
SLOTMAN, GJ ;
IBERTI, TJ ;
RACKOW, EC ;
SHAPIRO, MJ ;
GREENMAN, RL ;
REINES, HD ;
SHELLY, MP ;
THOMPSON, BW ;
LABRECQUE, JF ;
CATALANO, MA ;
KNAUS, WA ;
SADOFF, JC ;
ASTIZ, M ;
CARPATI, C ;
BONE, RC ;
FREIDMAN, B ;
MURE, AJ ;
BRATHWAITE, C ;
SHAPIRO, E ;
MELHORN, L ;
TAYLOR, R ;
KEEGAN, M ;
OBRIEN, J ;
SCHEIN, R ;
PENA, M ;
WASSERLOUF, M ;
OROPELLO, J ;
BENJAMIN, E ;
DELGUIDICE, R ;
EMMANUEL, G ;
LIE, T ;
ANDERSON, L ;
MARSHALL, J ;
DEMAJO, W ;
ROTSTEIN, O ;
FOSTER, D ;
ABRAHAM, E ;
MIDDLETON, H ;
PERRY, C ;
LEVY, H ;
FRY, DE ;
SIMPSON, SQ ;
CROWELL, RE ;
NEIDHART, M ;
STEVENS, D .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1994, 271 (23) :1836-1843
[8]   INFLUENCE OF AN ANTITUMOR NECROSIS FACTOR MONOCLONAL-ANTIBODY ON CYTOKINE LEVELS IN PATIENTS WITH SEPSIS [J].
FISHER, CJ ;
OPAL, SM ;
DHAINAUT, JF ;
STEPHENS, S ;
ZIMMERMAN, JL ;
NIGHTINGALE, P ;
HARRIS, SJ ;
SCHEIN, RMH ;
PANACEK, EA ;
VINCENT, JL ;
FOULKE, GE ;
WARREN, EL ;
GARRARD, C ;
PARK, G ;
BODMER, MW ;
COHEN, J ;
VANDERLINDEN, C ;
CROSS, AS ;
SADOFF, JC ;
GORECKI, J ;
DUBIN, HG ;
GARNER, C ;
KAYE, W ;
LANORE, JJ ;
MIRA, JP ;
ZIMMERMAN, J ;
DELLINGER, RP ;
TAYLOR, RW ;
DAHL, S ;
SHELLY, M ;
MORTIMER, A ;
EDWARDS, JD ;
KETT, DH ;
QUARTIN, A ;
PENA, MA ;
BAKKER, J ;
ALBERSON, TE ;
WALBY, W ;
RADCLIFFE, J ;
YOUNG, D ;
MCQUILLAM, P ;
BELLINGHAM, G ;
BURMAN, W ;
SADOFF, JS ;
YOUNG, L .
CRITICAL CARE MEDICINE, 1993, 21 (03) :318-327
[9]   Pumps utilized during continuous renal replacement therapy [J].
Golper, TA ;
Jacobs, AA .
SEMINARS IN DIALYSIS, 1996, 9 (02) :119-124
[10]  
GOLPER TA, 1993, CONT ISSUES NEPHROL, V27, P175